Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 7/20 | 0.40 |
| ▸ | RAB9A | P51151 | 7/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10280661 | 0.85 | MAPK13 (0.39) | FGFR1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL14191859 | 0.83 | FGFR1 (0.44) | FGFR1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL16346590 | 0.81 | FGFR1 (0.49) | FGFR1KDM4EALDH1A1MKNK1MKNK2 | |
| Hydrochloric Acid SCHEMBL5317456 | 0.77 | FGFR1 (0.49) | FGFR1NPC1RAB9AHPGDKDM4E | |
| SCHEMBL21363431 | 0.76 | KDM4C (0.42) | FGFR1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL23476802 | 0.75 | NPC1 (0.37) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL256337 | 0.75 | FGFR1 (0.53) | FGFR1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL29593970 | 0.75 | FGFR1 (0.53) | FGFR1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL2614317 | 0.75 | NPC1 (0.49) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL10183153 | 0.73 | MEN1 (0.41) | NPC1RAB9ASMN1; SMN2MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192669-A1 | COMPOUND, ORGANIC ELECTROLUMINESCENCE DEVICE AND ELECTRONIC APPARATUS | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20210047311-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | ARTIOS PHARMA LIMITED (GB) | 2021-02-18 | — | — | US | disclosed |
| US-10800769-B2 | Heterocyclic inhibitors of ATR kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-10-13 | — | — | US | disclosed |
| US-10738010-B2 | Process for preparing [(3-hydroxypyridine-2-carbonyl)amino] alkanoic acids, esters and amides | AKEBIA THERAPEUTICS, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20200102296-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | SHANGPHARMA LLC | 2020-04-02 | — | — | US | disclosed |
| US-10392376-B2 | Heterocyclic inhibitors of ATR kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-08-27 | — | — | US | disclosed |
| US-10246416-B2 | Process for preparing [(3-hydroxypyridine-2-carbonyl)amino] alkanoic acids, esters and amides | AKEBIA THERAPEUTICS, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-20190016713-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | ARTIOS PHARMA LIMITED (GB) | 2019-01-17 | — | — | US | disclosed |
| US-20180170942-A1 | POLYCYCLIC DERIVATIVES TARGETING RAL GTPASES AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIO INC (US) | 2018-06-21 | — | — | US | disclosed |
| US-20180072750-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2018-03-15 | — | — | US | disclosed |
| US-20110212951-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | EyePoint Pharmaceuticals, Inc. | 2011-09-01 | — | — | US | disclosed |
| US-20110059976-A1 | PYRIDO PYRIMIDINONES, DIHYDRO PYRIMIDO PYRIMIDINONES AND PTERIDINONES USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2011-03-10 | — | — | US | disclosed |
| US-7795444-B2 | Human protein tyrosine phosphatase inhibitors and methods of use | Warner Chilcott Company (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795444-B2 | Human protein tyrosine phosphatase inhibitors and methods of use | Warner Chilcott Company (US) | 2010-09-14 | — | — | US | disclosed |
| US-7767687-B2 | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors | BIOGEN IDEC MA INC. (US) | 2010-08-03 | — | — | US | disclosed |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20080293712-A1 | Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293712-A1 | Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080004267-A1 | Human protein tyrosine phosphatase inhibitors and methods of use | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | US | disclosed |
| US-20080004267-A1 | Human protein tyrosine phosphatase inhibitors and methods of use | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738010-B2 | Process for preparing [(3-hydroxypyridine-2-carbonyl)amino] alkanoic acids, esters and amides | HPD, APEH, P4HA1 | FGFR1 1183/4885NPC1 2586/4885RAB9A 1857/4885 |
| US-20180072750-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | DRD2, DRD1, DRD4 | FGFR1 1009/4885NPC1 542/4885RAB9A 616/4885 |
| US-20230192669-A1 | COMPOUND, ORGANIC ELECTROLUMINESCENCE DEVICE AND ELECTRONIC APPARATUS | ACHE, OR51E2, L1CAM | FGFR1 4273/4885NPC1 1759/4885RAB9A 1514/4885 |
| US-20110212951-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | FGFR1 1645/4885NPC1 3480/4885RAB9A 2893/4885 |
| US-10800769-B2 | Heterocyclic inhibitors of ATR kinase | ATR, CHEK1, CHEK2 | FGFR1 3470/4885NPC1 4504/4885RAB9A 3145/4885 |
| US-20180170942-A1 | POLYCYCLIC DERIVATIVES TARGETING RAL GTPASES AND THEIR THERAPEUTICAL APPLICATIONS | KRAS, HRAS, RALA | FGFR1 3180/4885NPC1 1365/4885RAB9A 35/4885 |
| US-10392376-B2 | Heterocyclic inhibitors of ATR kinase | ATR, CHEK1, CHEK2 | FGFR1 3470/4885NPC1 4504/4885RAB9A 3145/4885 |
| US-20200102296-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | ATR, CHEK1, CHEK2 | FGFR1 3470/4885NPC1 4504/4885RAB9A 3145/4885 |
| US-20110059976-A1 | PYRIDO PYRIMIDINONES, DIHYDRO PYRIMIDO PYRIMIDINONES AND PTERIDINONES USEFUL AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | FGFR1 197/4885NPC1 4187/4885RAB9A 524/4885 |
| US-20190016713-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | ATR, CHEK1, CHEK2 | FGFR1 3470/4885NPC1 4504/4885RAB9A 3145/4885 |
| US-20210047311-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | ATR, CHEK1, CHEK2 | FGFR1 3470/4885NPC1 4504/4885RAB9A 3145/4885 |
| US-20080293712-A1 | Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof | PDPK1, PDK2, PDK3 | FGFR1 1240/4885NPC1 2507/4885RAB9A 1685/4885 |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | FGFR1 10/4885NPC1 287/4885RAB9A 1218/4885 |
| US-10246416-B2 | Process for preparing [(3-hydroxypyridine-2-carbonyl)amino] alkanoic acids, esters and amides | HPD, APEH, P4HA1 | FGFR1 1183/4885NPC1 2586/4885RAB9A 1857/4885 |
| US-20080004267-A1 | Human protein tyrosine phosphatase inhibitors and methods of use | PTPRCAP, PTPRC, PPP5C | FGFR1 1645/4885NPC1 3480/4885RAB9A 2893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.